IP Library Patent Application 18055724
Patent Application
App. No. 18/055,724

EXOSOME DELIVERY OF CANCER THERAPEUTICS

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
18/055,724
Abstract

Chimeric expression constructs encoding an immunogenic polypeptide fused to a lactadherin domain are described. The compositions are useful for delivery of antigens to different cells, including cancer cells.

Claims (12)

1 . An exosome composition comprising a plasmid consisting of a nucleic acid encoding an immunogenic protein fused with a lactadherin C1C2 domain.

2 . The exosome composition of claim 1 wherein the immunogenic protein is a streptococcal antigen encoded by the nucleic sequence of SEQ ID NO:1.

3 . The exosome composition of claim 1 wherein the immunogenic protein is encoded by a nucleic acid selected from SEQ ID NO:2, SEQ ID NO:3 and SEQ ID NO:4.

4 . The exosome composition of claim 1 wherein the lactadherin C1C2 domain is encoded by a nucleic acid having the sequence of SEQ ID NO:5.

5 . The exosome composition of claim 1 wherein the plasmid is a lentiviral expression vector consisting of Emm55 DNA and lactadherin C1C2 domain DNA.

6 . An exosome composition comprising human peripheral blood mononuclear cells transfected with an mRNA or DNA of claim 1 .

7 . A method of delivering an immunogenic protein to a cell, comprising administering the exosome composition of claim 1 to a cancer cell.

8 . The method of claim 7 wherein the cancer cell is a lymphoma, peripheral blood mononuclear, dendritic cell or cancer cell.

9 . The method of claim 8 wherein the cancer cells are transfected ex vivo.

10 . The method of claim 7 wherein the immunogenic protein has the sequence of SEQ ID NO:1.

11 . The method of claim 9 wherein the exosome isolated from the transfected cancer cells is administered to said subject.

12 . A method of treating cancer comprising obtaining beta-cell lymphoma cells transfected ex vivo with exosomes containing the expression construct of claim 5 and administering the transfected exosomes to a lymphoma cancer subject in need thereof.

Assignments (1)
CHANGE OF NAME Recorded Mar 8, 2024
From: MORPHOGENESIS, INC.
To: TUHURA BIOSCIENCES, INC.
Reel/Frame 066778/0087 →